200, 82 Richmond St. East
Toronto, ON M5C 1P1
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. Jackie Peter Burnett||Pres, CEO & Chairman||495.68k||N/A||N/A|
|Mr. Guillermo Martin Delmonte||COO, Interim CFO & Corp. Sec. (Leave of Absence)||271.46k||N/A||N/A|
|Mr. Jose Roldan||Interim CFO||N/A||N/A||N/A|
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, and nutraceutical products in Uruguay, Italy, Poland, Brazil, and internationally. The company also engages in the resale of medical supplies products; and sale of medical devices and consumables, and veterinarian products. It offers XALEX, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; Cannabipiel Nite, Cannabipiel Body Lotion, Cannabipiel Hair Conditioner, Cannabipiel Liquid Soap, Cannabipiel Tite, Cannabipiel Cleaning Emulsion, Cannabipiel Shampoo, Cannabipiel Lite, and Cannabipiel Facial Tonic; and NETTAVET, a cannabis-based oral solution for dogs. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
RAMM Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.